The Clinical Problem of Neuropsychiatric Signs and Symptoms in Dementia

Overview

Journal Continuum (Minneap Minn)

Specialty Neurology

Date 2013 Apr 6

PMID 23558484

Citations 4

Authors

Anna Burke

Geri Hall

Pierre N Tariot

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This article reviews behavioral signs and symptoms of dementia that can lead to increased mortality, excessive cognitive and functional disability, early institutionalization, and increased caregiver burnout.

Recent Findings: Almost all patients with a dementia will develop significant behavioral disturbances at some point over the course of their illness. These behavioral signs and symptoms rarely fit into usual diagnostic classifications or meet full criteria for a formal major psychiatric disorder.

Summary: Treatment of behavioral signs and symptoms of dementia should include both pharmacologic and nonpharmacologic interventions. There are currently no treatments for these disturbances approved by the US Food and Drug Administration. Best judgment should be used in identifying dominant target symptoms and matching them to the most relevant drug class. Implementing nonpharmacologic interventions before the development of neuropsychiatric symptoms may prevent triggers related to a progressively lowered stress threshold and therefore is key in the treatment of all patients with a dementia.

Citing Articles

Predicting neuropsychiatric symptoms of persons with dementia in a day care center using a facial expression recognition system.

Chen L, Tsai T, Ho A, Li C, Ke L, Peng L Aging (Albany NY). 2022; 14(3):1280-1291.

PMID: 35113806 PMC: 8876896. DOI: 10.18632/aging.203869.

Hallucinations Predict Relapse After Discontinuation of Risperidone in Patients With Alzheimer's Disease and Psychosis or Agitation.

Lavretsky H Am J Psychiatry. 2017; 174(4):307-308.

PMID: 28366091 PMC: 5546409. DOI: 10.1176/appi.ajp.2016.16111314.

Determinants of Capacity to Consent to Research on Alzheimer's disease.

Palmer B, Harmell A, Pinto L, Dunn L, Kim S, Golshan S Clin Gerontol. 2017; 40(1):24-34.

PMID: 28154452 PMC: 5279898. DOI: 10.1080/07317115.2016.1197352.

Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations.

Patel A, Lee S, Andrews H, Pelton G, Schultz S, Sultzer D Am J Psychiatry. 2016; 174(4):362-369.

PMID: 27855483 PMC: 5378647. DOI: 10.1176/appi.ajp.2016.16020226.

References

Cummings J, Schneider E, Tariot P, Graham S . Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006; 67(1):57-63. DOI: 10.1212/01.wnl.0000223333.42368.f1. View

Alexopoulos G, Streim J, Carpenter D, Docherty J . Using antipsychotic agents in older patients. J Clin Psychiatry. 2004; 65 Suppl 2:5-99. View

Tariot P, Schneider L, Cummings J, Thomas R, Raman R, Jakimovich L . Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011; 68(8):853-61. PMC: 7003728. DOI: 10.1001/archgenpsychiatry.2011.72. View

Teri L, Logsdon R, Peskind E, Raskind M, Weiner M, Tractenberg R . Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000; 55(9):1271-8. DOI: 10.1212/wnl.55.9.1271. View

Gitlin L, Winter L, Burke J, Chernett N, Dennis M, Hauck W . Tailored activities to manage neuropsychiatric behaviors in persons with dementia and reduce caregiver burden: a randomized pilot study. Am J Geriatr Psychiatry. 2008; 16(3):229-39. PMC: 2803044. DOI: 10.1097/JGP.0b013e318160da72. View

Hall G, Buckwalter K . Progressively lowered stress threshold: a conceptual model for care of adults with Alzheimer's disease. Arch Psychiatr Nurs. 1987; 1(6):399-406. View

Wild R, Pettit T, Burns A . Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev. 2003; (3):CD003672. PMC: 7389676. DOI: 10.1002/14651858.CD003672. View

Ayalon L, Gum A, Feliciano L, Arean P . Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med. 2006; 166(20):2182-8. DOI: 10.1001/archinte.166.20.2182. View

Fox C, Crugel M, Maidment I, Auestad B, Coulton S, Treloar A . Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS One. 2012; 7(5):e35185. PMC: 3342281. DOI: 10.1371/journal.pone.0035185. View

10.

Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A . The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004; 63(2):214-9. DOI: 10.1212/01.wnl.0000129990.32253.7b. View

11.

Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R . Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012; 366(10):893-903. DOI: 10.1056/NEJMoa1106668. View

12.

Finkel S, Mintzer J, Dysken M, Krishnan K, Burt T, McRae T . A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004; 19(1):9-18. DOI: 10.1002/gps.998. View

13.

Jeste D, Caligiuri M, Paulsen J, Heaton R, Lacro J, Harris M . Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry. 1995; 52(9):756-65. DOI: 10.1001/archpsyc.1995.03950210050010. View

14.

Bains J, Birks J, Dening T . Antidepressants for treating depression in dementia. Cochrane Database Syst Rev. 2003; (4):CD003944. DOI: 10.1002/14651858.CD003944. View

15.

Bank A, Arguelles S, Rubert M, Eisdorfer C, Czaja S . The value of telephone support groups among ethnically diverse caregivers of persons with dementia. Gerontologist. 2006; 46(1):134-8. DOI: 10.1093/geront/46.1.134. View

16.

Savundranayagam M, Hummert M, Montgomery R . Investigating the effects of communication problems on caregiver burden. J Gerontol B Psychol Sci Soc Sci. 2005; 60(1):S48-55. DOI: 10.1093/geronb/60.1.s48. View

17.

Trinh N, Hoblyn J, Mohanty S, Yaffe K . Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003; 289(2):210-6. DOI: 10.1001/jama.289.2.210. View

18.

Howard R, Juszczak E, Ballard C, Bentham P, Brown R, Bullock R . Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007; 357(14):1382-92. DOI: 10.1056/NEJMoa066583. View

19.

Nobili A, Riva E, Tettamanti M, Lucca U, Liscio M, Petrucci B . The effect of a structured intervention on caregivers of patients with dementia and problem behaviors: a randomized controlled pilot study. Alzheimer Dis Assoc Disord. 2004; 18(2):75-82. DOI: 10.1097/01.wad.0000126618.98867.fc. View

20.

Herman R, Williams K . Elderspeak's influence on resistiveness to care: focus on behavioral events. Am J Alzheimers Dis Other Demen. 2009; 24(5):417-23. PMC: 2836897. DOI: 10.1177/1533317509341949. View